Overview
CAM5.2 is an immunohistochemical marker that detects low molecular weight cytokeratins, primarily keratin 8 (K8) and keratin 18 (K18), which are commonly expressed in secretory and glandular epithelial cells. It is also referred to as anti-cytokeratin and reacts with keratin 7 and keratin 8 antigens, which are widely distributed in human epithelia but are usually absent in stratified squamous epithelium.
It shows diffuse and strong cytoplasmic staining in most positive tumors, although a characteristic dot-like staining pattern may be seen in certain tumor types. It is positive in almost all glandular epithelia and adenocarcinomas, while squamous epithelium and squamous cell carcinomas generally remain negative. Due to this staining pattern, it is commonly used alongside pankeratin as part of an immunohistochemical panel to confirm or exclude epithelial origin in tissues, tumors, or tumor components.
The marker plays a significant role in identifying metastatic carcinoma, carcinoma subtyping, and determining epithelial differentiation in both primary and metastatic tumors. Detection is primarily performed using immunohistochemistry on formalin-fixed paraffin-embedded tissue, with fluorescent in situ hybridization (FISH) used in selected contexts. CAM5.2
Symptoms
CAM5.2 itself does not cause symptoms, as it is a diagnostic marker rather than a disease. Testing is performed in patients who present with clinical symptoms related to epithelial malignancies. These symptoms vary depending on tumor type and location and may include mass lesions, organ dysfunction, or symptoms related to metastatic disease.
CAM5.2 is frequently applied in cases where tumors of unknown origin are suspected, where residual tumor needs to be identified after treatment, or where metastatic carcinoma must be differentiated from non-epithelial malignancies such as gliomas or sarcomas.
Causes
CAM5.2 positivity reflects epithelial differentiation and cytokeratin expression rather than a causative condition. It is strongly expressed in adenocarcinomas and glandular epithelial tumors, including colorectal cancer, pancreatic cancer, Merkel cell carcinoma, and metastatic breast carcinoma. CAM5.2 is also useful in identifying metastatic carcinoma in sentinel lymph nodes and bone marrow, although false-positive results may occasionally occur in bone marrow evaluation.
Dot-like staining is characteristic of certain tumors such as neuroendocrine tumors, rhabdoid tumors, desmoplastic small round cell tumors, and Merkel cell carcinoma. CAM5.2 helps differentiate between metastatic carcinoma and glioblastoma, between uterine tumors resembling ovarian sex cord tumors and uterine smooth muscle tumors, and between Paget’s disease and pagetoid squamous cell carcinoma.
Negative CAM5.2 staining is typically seen in glioblastoma, uterine smooth muscle tumors, pagetoid squamous cell carcinoma, melanomas, and most non-epithelial tumors.
Risk Factors
Risk factors associated with CAM5.2 testing relate to the presence or suspicion of epithelial malignancies. Patients with known or suspected adenocarcinomas, metastatic tumors of unknown primary origin, or post-treatment residual disease are more likely to require CAM5.2 evaluation.
Interpretation of CAM5.2 staining can be influenced by tumor type, degree of differentiation, and tissue characteristics. Some sarcomas, spindle cell carcinomas, and rare non-epithelial tumors may show variable or low-level positivity, which requires correlation with other immunohistochemical markers. Proper internal positive controls are essential to ensure staining accuracy and standardization.
Prevention
There is no direct prevention related to CAM5.2 expression, as it is a diagnostic and classification marker rather than a modifiable risk factor. However, accurate diagnosis and disease management depend on correct tissue handling, fixation, and immunohistochemical processing.
Use of CAM5.2 in a comprehensive immunopanel, alongside markers such as CK7, CK20, EMA, GFAP, S100, WT1, PAX8, and CK5/6, improves diagnostic accuracy and helps prevent misclassification of tumors. Appropriate application of CAM5.2 aids in early and accurate identification of epithelial malignancies, guides further diagnostic workup, and supports optimal clinical decision-making.
